P081: Dual anti-HER-2 blockade with primary systemic therapy for HER-2 positive non-metastatic breast cancer can increase breast conservation rates: Benefit beyond survival. Issue 6 (June 2020) - Nigam, Shashank; Hakim, Aishah; Cuffolo, Giulio; Winter, Lucinda; Levitt, Nicky; Tuthill, Mark; Roy, Pankaj; Parulekar, Vaishali